# PDUFA dates September 2026: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2026-09

> 167 FDA catalysts are dated in September 2026, including 8 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in September 2026?

PDUFA dates in September 2026: TLX400 (TLX) on September 11, 2026; FAYUVI (rebisufligene etisparvovec, RARE) on September 19, 2026; MK-7962 (MRK) on September 21, 2026; ZANVASTRO™ (zilganersen, IONS) on September 22, 2026; ATEBRIOZ® (zilurgisertib, MIRM) on September 26, 2026; relutrigine (PRAX) on September 27, 2026; and 2 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2026-09)

Source: Press release filed with the SEC (EX-99), accession 0001140361-26-014495, https://www.sec.gov/Archives/edgar/data/2007191/000114036126014495/ef20070387_ex99-2.htm (retrieved 2026-11-12). Last confirmed 2026-04-14. Cite: https://sec-api.dev/fda-calendar/2026-09#answer

## PDUFA dates in September 2026

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| September 11, 2026 | Telix Pharmaceuticals Ltd | TLX | TLX400 |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000114036126014495/ef20070387_ex99-2.htm) |
| September 19, 2026 | Ultragenyx Pharmaceutical Inc. | RARE | FAYUVI (rebisufligene etisparvovec) | Sanfilippo syndrome type A | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1515673/000119312526333233/rare-20260630.htm) |
| September 21, 2026 | Merck & Co., Inc. | MRK | MK-7962 |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/mrk-20260630.htm) |
| September 22, 2026 | IONIS PHARMACEUTICALS INC | IONS | ZANVASTRO™ (zilganersen) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/874015/000087401526000251/form10q.htm) |
| September 26, 2026 | Mirum Pharmaceuticals, Inc. | MIRM | ATEBRIOZ® (zilurgisertib) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805xexx991.htm) |
| September 27, 2026 | Praxis Precision Medicines, Inc. | PRAX | relutrigine | SCN2A and SCN8A developmental and epileptic encephalopathies, or DEEs | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/praxisq12026pr.htm) |
| September 30, 2026 | BRISTOL MYERS SQUIBB CO | BMY |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/bmy-20260630.htm) |
| September 30, 2026 | Scholar Rock Holding Corp | SRRK | ISEMBYLD (apitegromab) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000119312526336715/srrk-ex99_1.htm) |

## All catalysts in September 2026

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 1, 2026 | [OCU410 trial start](https://sec-api.dev/pdufa/ocu410) | OCGN |  | completed | "On September 1, 2026, the Company announced that the first patient was dosed in the global Phase 3 registrational trial of OCU410 (AAV5-hRORA), its first-in-class modifier gene therapy candidate for Geographic Atrophy ("GA") secondary to dry age-related macular degeneration ("dAMD")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1372299/000110465926105968/tm2624985d1_8k.htm)) |
| September 1, 2026 | [Rhapsido® (remibrutinib) topline data readout](https://sec-api.dev/pdufa/remibrutinib) | NVS |  | completed, positive | "Basel, September 1, 2026 - Novartis today announced positive topline results from its Phase III REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis.1 Remibrutinib, a highly selective and potent oral Bruton's tyrosine kinase (BTK) inhibitor, demonstrated superiority versus teriflunomide in reducing annualized relapse rate (ARR) and inflammatory brain lesions with a favorable safety profile." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1114448/000117184326005824/f6k_090126.htm)) |
| September 1, 2026 | [Calquence (acalabrutinib) topline data readout](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Chronic Lymphocytic Leukemia | completed | "NCT04008706 (Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-04 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-09-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04008706?tab=results)) |
| September 2026 | [MINJUVI (tafasitamab) primary completion](https://sec-api.dev/pdufa/tafasitamab) | INCY | Diffuse Large B-cell Lymphoma | delayed | "NCT04824092 (Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-01 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04824092)) |
| September 1, 2026 | [Favezelimab/pembrolizumab topline data readout](https://sec-api.dev/pdufa/favezelimab-pembrolizumab) | MRK | Hodgkin Lymphoma | completed | "NCT05508867 (A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-03 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-09-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05508867?tab=results)) |
| September 2026 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Chronic Kidney Disease | delayed | "NCT06717698 (A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06717698)) |
| September 2, 2026 | [TEVA PHARMACEUTICAL INDUSTRIES LTD topline data readout](https://sec-api.dev/companies/teva/catalysts) | TEVA | Celiac disease | completed, positive | "On September 2, 2026, Teva announced positive topline results from an ongoing Phase 2a study of TEV-'408, in adults with Celiac disease." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/818686/000081868626000006/teva-20260930.htm)) |
| September 2, 2026 | [Scribe Therapeutics, Inc. earnings report](https://sec-api.dev/companies/sctx/catalysts) | SCTX |  | completed | "Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853921/000119312526380184/sctx-ex99_1.htm)) |
| September 2, 2026 | [Attovia Therapeutics, Inc. earnings report](https://sec-api.dev/companies/atto/catalysts) | ATTO |  | completed | "Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2058707/000119312526380215/atto-ex99_1.htm)) |
| September 2, 2026 | [Tarcocimab tedromer primary completion](https://sec-api.dev/pdufa/tarcocimab-tedromer) | KOD | Wet Age-related Macular Degeneration | completed | "NCT06556368 (A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-02 (ACTUAL); Lead Sponsor Kodiak Sciences Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06556368)) |
| September 3, 2026 | [ZANVASTRO™ (zilganersen) FDA approval](https://sec-api.dev/pdufa/zilganersen) | IONS | AxD in pediatric and adult patients | completed, approved | "On September 3, 2026, Ionis announced that the U.S. FDA has approved ZANVASTRO™ (zilganersen) for the treatment of AxD in pediatric and adult patients." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/874015/000114036126035657/ef20081649_8k.htm)) |
| September 3, 2026 | [Latigo Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/ltgo/catalysts) | LTGO |  | completed | "Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2056611/000119312526381912/ltgo-ex99_1.htm)) |
| September 3, 2026 | [CLYM116 interim data readout](https://sec-api.dev/pdufa/clym116) | CLYM |  | completed, positive | "CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced positive initial data from the ongoing Phase 1 trial evaluating CLYM116, an anti-APRIL monoclonal antibody, and provided updates on its strategy for further development in IgA nephropathy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768446/000119312526381060/d97033dex991.htm)) |
| September 3, 2026 | [JDQ443 primary completion](https://sec-api.dev/pdufa/jdq443) | NVS | Non-Small Cell Lung Cancer | withdrawn | "NCT05132075 (Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-09-03 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05132075)) |
| September 3, 2026 | [Ziltivekimab primary completion](https://sec-api.dev/pdufa/ziltivekimab) | NVO | Heart Failure | withdrawn | "NCT05636176 (A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-09-03 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05636176)) |
| September 3, 2026 | [Nurtec Odt (rimegepant sulfate) topline data readout](https://sec-api.dev/pdufa/rimegepant) | PFE | Migraine | completed | "NCT05810038 (A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-25 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-09-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05810038?tab=results)) |
| September 3, 2026 | [AbbVie Inc. primary completion](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Mid Face Volume Deficit | completed | "NCT07032597 (A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-03 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07032597)) |
| September 3, 2026 | [AZD0780 primary completion](https://sec-api.dev/pdufa/azd0780) | AZN | Dyslipidaemia | completed | "NCT07218900 (A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-09-03 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218900)) |
| September 4, 2026 | [Etcamah (camizestrant) FDA approval](https://sec-api.dev/pdufa/camizestrant) | AZN |  | completed, approved | "Etcamah \| camizestrant \| 9/4/2026 \| To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| September 4, 2026 | [HETLIOZ® (tasimelteon) primary completion](https://sec-api.dev/pdufa/tasimelteon) | VNDA | Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorders | completed | "NCT04652882 (Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-04 (ACTUAL); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04652882)) |
| September 4, 2026 | [Sar441344 iv primary completion](https://sec-api.dev/pdufa/sar441344-iv) | SNY | Systemic Lupus Erythematosus | completed | "NCT05039840 (Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-04 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05039840)) |
| September 4, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight; Type 2 Diabetes | completed | "NCT05872620 (A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-08 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-09-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05872620?tab=results)) |
| September 4, 2026 | [Dtpa vaccine primary completion](https://sec-api.dev/pdufa/dtpa-vaccine) | GSK | Diphtheria-Tetanus-acellular Pertussis Vaccines | completed | "NCT07596173 (A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-04 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07596173)) |
| September 7, 2026 | [Eteplirsen primary completion](https://sec-api.dev/pdufa/eteplirsen) | SRPT | Muscular Dystrophy, Duchenne | completed | "NCT03992430 (A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-07 (ACTUAL); Lead Sponsor Sarepta Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03992430)) |
| September 7, 2026 | [Sevasemten primary completion](https://sec-api.dev/pdufa/sevasemten) | EWTX | Becker Muscular Dystrophy | completed | "NCT05291091 (Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-09-07 (ACTUAL); Lead Sponsor Edgewise Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05291091)) |
| September 7, 2026 | [Domvanalimab primary completion](https://sec-api.dev/pdufa/domvanalimab) | RCUS | Gastrointestinal Tract Malignancies | completed | "NCT05329766 (A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-09-07 (ACTUAL); Lead Sponsor Arcus Biosciences, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05329766)) |
| September 7, 2026 | [Tulisokibart primary completion](https://sec-api.dev/pdufa/tulisokibart) | MRK | Arthritis, Rheumatoid | completed | "NCT07176390 (A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-07 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07176390)) |
| September 8, 2026 | [Apnimed, Inc. earnings report](https://sec-api.dev/companies/apmd/catalysts) | APMD |  | completed | "Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526385355/apmd-ex99_1.htm)) |
| September 8, 2026 | [ACCG-2671 topline data readout](https://sec-api.dev/pdufa/accg-2671) | GPCR |  | completed, positive | "On September 8, 2026, the Company reported positive topline data for" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1888886/000110465926105688/tm2624945d1_8k.htm)) |
| September 8, 2026 | [Braveheart Bio, Inc. earnings report](https://sec-api.dev/companies/brve/catalysts) | BRVE |  | completed | "Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2131524/000162828026060904/brve-q2268xkex991xearnings.htm)) |
| September 8, 2026 | [SPY003 topline data readout](https://sec-api.dev/pdufa/spy003) | SYRE |  | completed, positive | "On September 8, 2026, the Company announced positive 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY003, an anti-IL-23 being investigated for the treatment of moderately-to-severely active UC." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000113/syre-20260908.htm)) |
| September 8, 2026 | [MRT-6160 trial start](https://sec-api.dev/pdufa/mrt-6160) | GLUE | Sjögren's disease | completed | "BOSTON, Mass., September 8, 2026 - Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Novartis has initiated a Phase 2 clinical study for the VAV1-directed MGD MRT-6160 (DDY391) in people living with Sjögren's disease (SjD), the second most prevalent rheumatic autoimmune disease1." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312526384360/glue-ex99_1.htm)) |
| September 8, 2026 | [Erbitux® (cetuximab) trial start](https://sec-api.dev/pdufa/cetuximab) | ANL | CEACAM5-enriched RAS-addicted solid tumors | completed | "8th, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) ("Adlai Nortye" or the "Company"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that the first patient has been dosed with AN4035 in Australia, initiating the global Phase I trial in patients with CEACAM5-enriched RAS-addicted solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1944552/000121390026097850/ea030480101ex99-1.htm)) |
| September 8, 2026 | [Strattera (atomoxetine) NDA/BLA acceptance](https://sec-api.dev/pdufa/atomoxetine) | APMD | with obstructive sleep apnea | completed | "Announced the FDA accepted for review the New Drug Application ("NDA") for AD109 (proposed proprietary name Oxnimbi) for the treatment of adults with obstructive sleep apnea ("OSA")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526385355/apmd-ex99_1.htm)) |
| September 8, 2026 | [EnGene Therapeutics Inc. earnings report](https://sec-api.dev/companies/engn/catalysts) | ENGN |  | completed | "Exhibit 99.1 enGene Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1980845/000119312526384380/engn-ex99_1.htm)) |
| September 8, 2026 | [Bitopertin primary completion](https://sec-api.dev/pdufa/bitopertin) | IRON | Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP) | completed | "NCT06910358 (Study of Bitopertin in Participants With EPP or XLP (APOLLO)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-08 (ACTUAL); Lead Sponsor Disc Medicine, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06910358)) |
| September 9, 2026 | [NEO100 (NEO100) topline data readout](https://sec-api.dev/pdufa/neo100) | NTHI |  | completed, positive | "The purchase follows the Company's $15 million registered direct offering announced on September 9, 2026, and extends a series of open-market purchases by NeOnc's senior leadership since the Company reported positive topline Phase 2a results for intranasal NEO100™ on August 12, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1979414/000182912626010156/neonctechnologies_ex99-1.htm)) |
| September 9, 2026 | [Ameluz (aminolevulinic acid hydrochloride) label expansion decision](https://sec-api.dev/pdufa/aminolevulinic-acid) | BFRI |  | completed, approved | "NDA208081 SUPPL-40 (Efficacy): submission_status AP, submission_status_date 20260909, review_priority STANDARD; sponsor_name BIOFRONTERA; product AMELUZ (AMINOLEVULINIC ACID HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208081%22)) |
| September 9, 2026 | [AX-0811 trial start](https://sec-api.dev/pdufa/ax-0811) | PRQR |  | completed | "Netherlands & CAMBRIDGE, Mass., September 9, 2026 - ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612940/000110465926106138/tm2624953d1_ex99-1.htm)) |
| September 9, 2026 | [Gb002 (seralutinib) primary completion](https://sec-api.dev/pdufa/gb002-seralutinib) | GOSS | Pulmonary Arterial Hypertension | withdrawn | "NCT04816604 (Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-09 (ACTUAL); Lead Sponsor Gossamer Bio USA, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04816604)) |
| September 9, 2026 | [EYP-1901 primary completion](https://sec-api.dev/pdufa/eyp-1901) | EYPT | Wet Age Related Macular Degeneration; wAMD | completed | "NCT06683742 (A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-09 (ACTUAL); Lead Sponsor EyePoint Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06683742)) |
| September 9, 2026 | [Cab la primary completion](https://sec-api.dev/pdufa/cab-la) | GSK | HIV Infections | completed | "NCT06741397 (A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-09 (ACTUAL); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06741397)) |
| September 10, 2026 | [CHAMPIONS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/csbr/catalysts) | CSBR |  | completed | "Hackensack, NJ - September 10, 2026 - Champions Oncology, Inc. (Nasdaq: CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2027, ended July 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/771856/000162828026061383/csbr8-k7312026exhibit991xq1.htm)) |
| September 10, 2026 | [Obefazimod topline data readout](https://sec-api.dev/pdufa/obefazimod) | ABVX | Ulcerative Colitis | completed | "NCT05507203 (ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Abivax S.A.; Results First Posted 2026-09-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05507203?tab=results)) |
| September 10, 2026 | [Obefazimod topline data readout](https://sec-api.dev/pdufa/obefazimod) | ABVX | Ulcerative Colitis | completed | "NCT05507216 (ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Abivax S.A.; Results First Posted 2026-09-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05507216?tab=results)) |
| September 10, 2026 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Head and Neck | completed | "NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-10 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06062420)) |
| September 10, 2026 | [Itepekimab (sar440340) primary completion](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Obstructive Pulmonary Disease | completed | "NCT06208306 (A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-10 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06208306)) |
| September 2026 | [PCV-20 primary completion](https://sec-api.dev/pdufa/pcv-20) | GSK | Chickenpox | delayed | "NCT06855160 (A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09-10 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06855160)) |
| September 11, 2026 | [ISEMBYLD (apitegromab) FDA approval](https://sec-api.dev/pdufa/apitegromab) | SRRK | SMA in adults and children 2 years of age and older | completed, approved | "On September 11, 2026, the Company announced that the FDA has approved ISEMBYLD™ (apitegromab-mstn) for the treatment of SMA in adults and children 2 years of age and older who are currently receiving a survival SMN2 targeted treatment." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1727196/000110465926107273/tm2625362d1_8k.htm)) |
| September 11, 2026 | [ACADIA PHARMACEUTICALS INC complete response letter (CRL)](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | completed, complete response letter | "And, on April 5, 2021, Acadia announced that the FDA had issued a Complete Response Letter ("CRL"), stating that it could not approve the sNDA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526389400/d143428dex991.htm)) |
| September 11, 2026 | [Isembyld (apitegromab-mstn) FDA approval](https://sec-api.dev/pdufa/apitegromab-mstn) | SRRK |  | completed, approved | "Isembyld \| apitegromab-mstn \| 9/11/2026 \| To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| September 11, 2026 | [TLX400 PDUFA date](https://sec-api.dev/pdufa/tlx400) | TLX |  | scheduled | "Solutions TLX591-Tx for mCRPC, ProstACT Global Part 1 data readout Part 2 international site expansion, interim analysis1 TLX250-Tx for ccRCC, LUTEON, open for recruitment TLX090-Tx for metastatic bone pain, SOLACE, enrollment completion TLX592-Tx for mCRPC, AlphaPRO, patient dosing TLX102-Tx for recurrent GBM and leptomeningeal disease, trial commencement TLX252-Tx for ccRCC and other CAIX-expressing tumors, trial commencement TLX400-Tx recommencement of clinical activity Pixclara2 NDA resubmission (U.S.) accepted, PDUFA goal date September 11, 2026 Zircaix2 BLA resubmission (U.S.) Illuccix, Gozellix BiPASS™ enrollment completion Illuccix Japan trial, enrollment completion Illuccix" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000114036126014495/ef20070387_ex99-2.htm)) |
| September 11, 2026 | [TLX400 NDA/BLA submission](https://sec-api.dev/pdufa/tlx400) | TLX |  | scheduled | "Solutions TLX591-Tx for mCRPC, ProstACT Global Part 1 data readout Part 2 international site expansion, interim analysis1 TLX250-Tx for ccRCC, LUTEON, open for recruitment TLX090-Tx for metastatic bone pain, SOLACE, enrollment completion TLX592-Tx for mCRPC, AlphaPRO, patient dosing TLX102-Tx for recurrent GBM and leptomeningeal disease, trial commencement TLX252-Tx for ccRCC and other CAIX-expressing tumors, trial commencement TLX400-Tx recommencement of clinical activity Pixclara2 NDA resubmission (U.S.) accepted, PDUFA goal date September 11, 2026 Zircaix2 BLA resubmission (U.S.) Illuccix, Gozellix BiPASS™ enrollment completion Illuccix Japan trial, enrollment completion Illuccix" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000114036126014495/ef20070387_ex99-2.htm)) |
| September 11, 2026 | [Pixclara (floretyrosine f-18) FDA approval](https://sec-api.dev/pdufa/floretyrosine-f-18) | TLX |  | completed, approved | "Pixclara \| floretyrosine F 18 \| 9/11/2026 \| To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| September 11, 2026 | [Joenja® (leniolisib) label expansion decision](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed, approved | "On September 11, 2026, we announced that the U.S. Food and Drug Administration (FDA) had approved our supplemental New Drug Application (sNDA) for 40 mg and 50 mg twice-daily dosing of Joenja as a treatment for children aged 4 to 11 years weighing at least 27 kg with APDS." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000049/a2026q3pressrelease.htm)) |
| September 11, 2026 | [VOQUEZNA® (vonoprazan) primary completion](https://sec-api.dev/pdufa/vonoprazan) | PHAT | Eosinophilic Esophagitis | completed | "NCT06851559 (A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-11 (ACTUAL); Lead Sponsor Phathom Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06851559)) |
| September 14, 2026 | [Ameluz (ameluz) FDA approval](https://sec-api.dev/pdufa/ameluz) | BFRI | Superficial Basal Cell Carcinoma | completed, approved | "Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315226042508/ex99-1.htm)) |
| September 14, 2026 | [Pixclara (pixclara) FDA approval](https://sec-api.dev/pdufa/pixclara) | TLX |  | completed, approved | "Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026061892/pixclaraapprovalvfinal.htm)) |
| September 14, 2026 | [Biofrontera Inc. label expansion decision](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed, approved | "September 14, 2026, Biofrontera Inc. (the "Company") issued a press release announcing that it has received notification from the U.S. Food and Drug Administration (the "FDA") that the FDA had approved the Company's supplemental New Drug" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1858685/000149315226042508/form8-k.htm)) |
| September 14, 2026 | [CRB-913 topline data readout](https://sec-api.dev/pdufa/crb-913) | CRBP | obesity | completed, positive | "On September 14, 2026, the Company announced positive topline data from the CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1595097/000119312526389829/crbp-20260914.htm)) |
| September 14, 2026 | [Benitec Biopharma Inc. earnings report](https://sec-api.dev/companies/bntc/catalysts) | BNTC |  | completed | "HAYWARD, Calif., Sep. 14, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or the "Company"), a clinical-stage biotechnology company developing disease-modifying genetic medicines for life-threatening, genetically defined diseases, based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its full fiscal year ended June 30, 2026, and provided an update on recent regulatory interactions and upcoming clinical data presentations." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1808898/000119312526390539/bntc-ex99_1.htm)) |
| September 14, 2026 | [Qfitlia™ (fitusiran) primary completion](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | completed | "NCT03754790 (Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-14 (ACTUAL); Lead Sponsor Genzyme, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03754790)) |
| September 14, 2026 | [Tagrisso® (osimertinib) label expansion decision](https://sec-api.dev/pdufa/osimertinib) | AZN |  | completed, approved | "NDA208065 SUPPL-35 (Efficacy): submission_status AP, submission_status_date 20260914, review_priority STANDARD; sponsor_name ASTRAZENECA; product TAGRISSO (OSIMERTINIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208065%22)) |
| September 15, 2026 | [Quantum Biopharma Ltd. FDA approval](https://sec-api.dev/companies/qntm/catalysts) | QNTM | progressive MS | completed, approved | "Recently Quantum BioPharma announced that the U.S. Food and Drug Administration (FDA) had approved its Investigational New Drug application for Lucid-MS, to begin Phase 2 trials for the very first time to advance its patented, first-in-class multiple sclerosis ("MS") program in patients with progressive MS. This is currently an area of substantial unmet medical need within a global MS therapeutics market anticipated to reach approximately US$38.62 billion by 2030 (Grand View Research, 2026)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771885/000117184326006047/exh_991.htm)) |
| September 15, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06045221 (A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-22 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-09-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06045221?tab=results)) |
| September 16, 2026 | [Truqap (capivasertib) label expansion decision](https://sec-api.dev/pdufa/capivasertib) | AZN |  | completed, approved | "NDA218197 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20260916, review_priority STANDARD; sponsor_name ASTRAZENECA; product TRUQAP (CAPIVASERTIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218197%22)) |
| September 16, 2026 | [Exa-cel topline data readout](https://sec-api.dev/pdufa/exa-cel) | VRTX | Sickle Cell Disease; Hematological Diseases; Hemoglobinopathies | completed | "NCT03745287 (A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-07-07 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated; Results First Posted 2026-09-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03745287?tab=results)) |
| September 16, 2026 | [MRNA-1010 topline data readout](https://sec-api.dev/pdufa/mrna-1010) | MRNA | Seasonal Influenza | completed | "NCT06602024 (A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-21 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-09-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06602024?tab=results)) |
| September 16, 2026 | [VOXZOGO (vosoritide) primary completion](https://sec-api.dev/pdufa/vosoritide) | BMRN | Noonan Syndrome | withdrawn | "NCT06668805 (A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-16 (ACTUAL); Lead Sponsor BioMarin Pharmaceutical." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06668805)) |
| September 16, 2026 | [Dt402 (r-enantiomer of 3,4-methylenedioxymethamphetamine (mdma)) primary completion](https://sec-api.dev/pdufa/dt402-r-enantiomer-of-3-4-methylenedioxymethamphetamine-mdma) | DFTX | Autism Spectrum Disorder; ASD | completed | "NCT07303907 (A Phase 2A Trial of DT402 for Autism Spectrum Disorder): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-09-16 (ACTUAL); Lead Sponsor Definium Therapeutics US, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07303907)) |
| September 16, 2026 | [Ibtrozi (taletrectinib adipate) label expansion decision](https://sec-api.dev/pdufa/taletrectinib-adipate) | NUVB |  | completed, approved | "NDA219713 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20260916, review_priority STANDARD; sponsor_name NUVATION; product IBTROZI (TALETRECTINIB ADIPATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219713%22)) |
| September 17, 2026 | [PEDMARK (pedmark) trial start](https://sec-api.dev/pdufa/pedmark) | FENC |  | completed | "Fennec Pharmaceuticals Announces ORAL PRESENTATION OF DETAILED Results From Investigator-Initiated Phase 2 STS-J01 Clinical Study of PEDMARK® in Japan AT SIOP 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1211583/000110465926108565/fencf-20260917xex99d1.htm)) |
| September 17, 2026 | [Anaphylm™ (dibutepinephrine) NDA/BLA submission](https://sec-api.dev/pdufa/dibutepinephrine) | AQST | Type I allergic reactions | completed | "On September 17, 2026, the Company issued a press release announcing it has resubmitted its New Drug Application to the U.S. Food and Drug Administration for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000044/aqst-20260914.htm)) |
| September 17, 2026 | [Cisplatin trial start](https://sec-api.dev/pdufa/cisplatin) | FENC |  | completed | "On September 17, 2026, Fennec Pharmaceuticals Inc. (the "Company") announced positive results from the investigator-initiated Phase 2 STS-J01 clinical study of PEDMARK® in Japan, which met its primary endpoint and demonstrated significant hearing protection without evidence of interference with cisplatin antitumor activity." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1211583/000110465926108565/fencf-20260917x8k.htm)) |
| September 17, 2026 | [Domvanalimab primary completion](https://sec-api.dev/pdufa/domvanalimab) | RCUS |  | completed | "NCT04736173 (Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-09-17 (ACTUAL); Lead Sponsor Arcus Biosciences, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04736173)) |
| September 17, 2026 | [Foralumab primary completion](https://sec-api.dev/pdufa/foralumab) | TLSA | Secondary Progressive Multiple Sclerosis | completed | "NCT06292923 (A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-09-17 (ACTUAL); Lead Sponsor Tiziana Life Sciences LTD." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06292923)) |
| September 2026 | [Biological/vaccine primary completion](https://sec-api.dev/pdufa/biological-vaccine) | VRTX | Type 1 Diabetes; Kidney Transplant | delayed | "NCT06832410 (An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09-17 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06832410)) |
| September 17, 2026 | [QCZ484 primary completion](https://sec-api.dev/pdufa/qcz484) | NVS | Hypertension | completed | "NCT06857955 (A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-17 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06857955)) |
| September 17, 2026 | [PCV20 primary completion](https://sec-api.dev/pdufa/pcv20) | PCVX | Pneumococcal Disease | completed | "NCT07284654 (Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-17 (ACTUAL); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284654)) |
| September 18, 2026 | [INTEGRATED BIOPHARMA INC interim data readout](https://sec-api.dev/companies/inbp/catalysts) | INBP |  | scheduled | "After taking into consideration our interim results and current projections, management believes that operations, together with our credit facilities and equipment financing will support our working capital requirements at least through the twelve-month period ending September 18, 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1016504/000143774925029711/inbp20250630_10k.htm)) |
| September 18, 2026 | [BlossomHill Therapeutics, Inc. earnings report](https://sec-api.dev/companies/blsm/catalysts) | BLSM |  | completed | "BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1839970/000119312526395031/d266261dex991.htm)) |
| September 18, 2026 | [VERZENIO (abemaciclib) label expansion decision](https://sec-api.dev/pdufa/abemaciclib) | LLY |  | completed, approved | "NDA208716 SUPPL-22 (Efficacy): submission_status AP, submission_status_date 20260918, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22)) |
| September 18, 2026 | [Inluriyo™ (imlunestrant) label expansion decision](https://sec-api.dev/pdufa/imlunestrant) | LLY |  | completed, approved | "NDA218881 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20260918, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product INLURIYO (IMLUNESTRANT TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218881%22)) |
| September 18, 2026 | [Verekitug (upb-101) topline data readout](https://sec-api.dev/pdufa/verekitug-upb-101) | UPB | Chronic Rhinosinusitis With Nasal Polyps | completed | "NCT06164704 (A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-07 (ACTUAL); Lead Sponsor Upstream Bio Inc.; Results First Posted 2026-09-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06164704?tab=results)) |
| September 18, 2026 | [PAVBLU® (aflibercept) topline data readout](https://sec-api.dev/pdufa/aflibercept) | REGN | Neovascular Age-Related Macular Degeneration; Diabetic Macular Edema | completed | "NCT06491914 (A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-26 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals; Results First Posted 2026-09-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06491914?tab=results)) |
| September 18, 2026 | [APPROACH (tibulizumab) primary completion](https://sec-api.dev/pdufa/tibulizumab) | ZURA | Hidradenitis Suppurativa (HS) | completed | "NCT06993610 (Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-18 (ACTUAL); Lead Sponsor Zura Bio Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06993610)) |
| September 19, 2026 | [FAYUVI (rebisufligene etisparvovec) PDUFA date](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE | Sanfilippo syndrome type A | scheduled | "In April 2026, we announced that the FDA had accepted our resubmitted BLA seeking accelerated approval for UX111 as a treatment for patients with Sanfilippo syndrome Type A. The FDA granted the BLA Priority Review and assigned a PDUFA action date of September 19, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1515673/000119312526333233/rare-20260630.htm)) |
| September 20, 2026 | [CUE-221 topline data readout](https://sec-api.dev/pdufa/cue-221) | CUE |  | completed, positive | "On September 20, 2026, the Company announced positive topline data from a Phase 2 clinical trial of CUE-221 in CSU conducted in China by Genesis Life Sciences, an affiliate of Ascendant Health Ltd. This Phase 2 clinical trial enrolled 145 participants with moderate to severe CSU whose disease remained inadequately controlled despite treatment with H1-antihistamines." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1645460/000119312526396094/d21238d8k.htm)) |
| September 21, 2026 | [MK-7962 PDUFA date](https://sec-api.dev/pdufa/mk-7962) | MRK |  | scheduled | "The FDA set a PDUFA date of September 21, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/mrk-20260630.htm)) |
| September 21, 2026 | [Neuropeptide topline data readout](https://sec-api.dev/pdufa/neuropeptide) | ALKS | attention-deficit hyperactivity disorder | completed, positive | "On September 21, 2026, the Company announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the Company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1520262/000119312526396065/alks-20260921.htm)) |
| September 2026 | [CardiolRx™ (cardiolrx) primary completion](https://sec-api.dev/pdufa/cardiolrx) | CRDL | Recurrent Pericarditis | delayed | "NCT06708299 (CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09-21 (ESTIMATED); Lead Sponsor Cardiol Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06708299)) |
| September 21, 2026 | [Fasenra (benralizumab) primary completion](https://sec-api.dev/pdufa/benralizumab) | AZN | Eosinophilic Asthma | completed | "NCT06750289 (Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-21 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06750289)) |
| September 21, 2026 | [ATI-045 primary completion](https://sec-api.dev/pdufa/ati-045) | ACRS | Atopic Dermatitis; Atopic; Dermatitis | completed | "NCT07011706 (ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-21 (ACTUAL); Lead Sponsor Aclaris Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07011706)) |
| September 21, 2026 | [Winrevair (sotatercept-csrk) label expansion decision](https://sec-api.dev/pdufa/sotatercept-csrk) | MRK |  | completed, approved | "BLA761363 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20260921, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product WINREVAIR (SOTATERCEPT-CSRK)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761363%22)) |
| September 22, 2026 | [AYTU BIOPHARMA, INC earnings report](https://sec-api.dev/companies/aytu/catalysts) | AYTU |  | completed | "Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1385818/000143774926030900/ex_955176.htm)) |
| September 22, 2026 | [VK2735 topline data readout](https://sec-api.dev/pdufa/vk2735) | VKTX |  | completed, positive | "SAN DIEGO, CA - September 22, 2026 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company's maintenance study of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526397219/vktx-ex99_1.htm)) |
| September 22, 2026 | [Joenja® (leniolisib) topline data readout](https://sec-api.dev/pdufa/leniolisib) | PHAR | genetically defined primary immunodeficiencies | completed, positive | "Leiden, the Netherlands, September 22, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that a late-breaking abstract highlighting positive topline data from its Phase II trial with leniolisib in genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kd signaling has been accepted at the 22nd Biennial Meeting of the European Society for Immunodeficiencies (ESID), which will take place October 14-17, in the Netherlands." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000039/pharmingannouncespositivep.htm)) |
| September 22, 2026 | [ZANVASTRO™ (zilganersen) PDUFA date](https://sec-api.dev/pdufa/zilganersen) | IONS |  | completed, approved | "The FDA has granted Priority Review of zilganersen, with a Prescription Drug User Fee Act, or PDUFA, action date of September 22, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/874015/000087401526000251/form10q.htm)) |
| September 22, 2026 | [Exkivity (mobocertinib succinate) primary completion](https://sec-api.dev/pdufa/mobocertinib) | TAK | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | "NCT04129502 (TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04129502)) |
| September 22, 2026 | [Opdivo® (nivolumab) topline data readout](https://sec-api.dev/pdufa/nivolumab) | BMY | Clear Cell Renal Cell Carcinoma | completed | "NCT04810078 (A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-09-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04810078?tab=results)) |
| September 22, 2026 | [BEQALZI™ (sonrotoclax) primary completion](https://sec-api.dev/pdufa/sonrotoclax) | ONC |  | completed | "NCT05952037 (A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05952037)) |
| September 22, 2026 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Asthma | withdrawn | "NCT06033833 (Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06033833)) |
| September 22, 2026 | [TRUTAKNA (atacicept) primary completion](https://sec-api.dev/pdufa/atacicept) | VERA | IgA Nephropathy (IgAN); Berger Disease | completed | "NCT07020923 (Monthly Dosing of Atacicept in IgAN): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor Vera Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07020923)) |
| September 22, 2026 | [Bnt162b2 vaccine primary completion](https://sec-api.dev/pdufa/bnt162b2-vaccine) | BNTX | COVID-19; SARS-COV-2 Infection | completed | "NCT07300839 (A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07300839)) |
| September 23, 2026 | [Seralutinib NDA/BLA submission](https://sec-api.dev/pdufa/seralutinib) | GOSS | pulmonary arterial hypertension | completed | "On September 23, 2026, Gossamer Bio, Inc. (the "Company") announced that it submitted a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in September 2026 for seralutinib for the treatment of pulmonary arterial hypertension ("PAH")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000104/goss-20260923.htm)) |
| September 23, 2026 | [Sefaxersen interim data readout](https://sec-api.dev/pdufa/sefaxersen) | IONS | primary IgA nephropathy | completed, positive | "On September 23, 2026, Ionis Pharmaceuticals, Inc. ("Ionis") issued a press release announcing that Ionis and its partner, Roche Holding Ltd. ("Roche"), reported positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy ("IgAN")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/874015/000114036126037371/ef20082626_8k.htm)) |
| September 23, 2026 | [Onswik (insulin efsitora alfa-gobe) FDA approval](https://sec-api.dev/pdufa/insulin-efsitora-alfa-gobe) | LLY |  | completed, approved | "Onswik \| insulin efsitora alfa-gobe \| 9/23/2026 \| To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| September 23, 2026 | [PF-06835375 primary completion](https://sec-api.dev/pdufa/pf-06835375) | PFE | Primary Immune Thrombocytopenia | withdrawn | "NCT05070845 (Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-23 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05070845)) |
| September 23, 2026 | [Itepekimab (sar440340) primary completion](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Rhinosinusitis With Nasal Polyps | completed | "NCT06834347 (A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-23 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06834347)) |
| September 24, 2026 | [Rezolute, Inc. earnings report](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | completed | "Calif., September 24, 2026 - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110412/tm2625842d1_ex99-1.htm)) |
| September 24, 2026 | [Mivocabtagene autoleucel topline data readout](https://sec-api.dev/pdufa/mivocabtagene-autoleucel) | KYTX | neurologic autoimmune diseases, today | completed, positive | "EMERYVILLE, Calif., Sept. 24, 2026 -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced positive one-year topline data from KYSA-8, its registrational trial of miv-cel (mivocabtagene autoleucel, KYV-101) in patients with stiff person syndrome (SPS), and positive topline longer-term follow-up data from the Phase 2 portion of KYSA-6, its registrational trial in patients with generalized myasthenia gravis (gMG)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1994702/000119312526400062/kytx-ex99_1.htm)) |
| September 24, 2026 | [WELIREG® (belzutifan) label expansion decision](https://sec-api.dev/pdufa/belzutifan) | MRK |  | completed, approved | "NDA215383 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20260924, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product WELIREG (BELZUTIFAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215383%22)) |
| September 24, 2026 | [Itepekimab (sar440340) primary completion](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Rhinosinusitis With Nasal Polyps | completed | "NCT06834360 (A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-24 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06834360)) |
| September 25, 2026 | [Joenja® (leniolisib) NDA/BLA acceptance](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed | "Leiden, the Netherlands, September 25, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for lower doses of Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, for children aged 4 years and older who weigh between 13 kg and 27 kg with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000041/pharmingannouncesusfdaacce.htm)) |
| September 25, 2026 | [INTEGRATED BIOPHARMA INC earnings report](https://sec-api.dev/companies/inbp/catalysts) | INBP |  | completed | "HILLSIDE, NEW JERSEY (September 25, 2026) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1016504/000143774926031247/ex_1019813.htm)) |
| September 25, 2026 | [OLUMIANT® (baricitinib) label expansion decision](https://sec-api.dev/pdufa/baricitinib) | LLY |  | completed, approved | "NDA207924 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20260925, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product OLUMIANT (BARICITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207924%22)) |
| September 25, 2026 | [Degevma (denosumab-adet) FDA approval](https://sec-api.dev/pdufa/denosumab-adet) | TEVA |  | completed, approved | "BLA761481 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260925, review_priority STANDARD; sponsor_name TEVA PHARMACEUTICALS, INC.; product DEGEVMA (DENOSUMAB-ADET)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761481%22)) |
| September 25, 2026 | [Jaypirca (pirtobrutinib) topline data readout](https://sec-api.dev/pdufa/pirtobrutinib) | LLY | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | completed | "NCT05023980 (A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-11 (ACTUAL); Lead Sponsor Loxo Oncology, Inc.; Results First Posted 2026-09-25." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05023980?tab=results)) |
| September 25, 2026 | [Juvmo (tavapadon) FDA approval](https://sec-api.dev/pdufa/tavapadon) | ABBV | To treat Parkinson’s disease in adults | completed, approved | "Juvmo \| tavapadon \| 9/25/2026 \| To treat Parkinson’s disease in adults" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| September 25, 2026 | [ATEBRIOZ® (zilurgisertib) FDA approval](https://sec-api.dev/pdufa/zilurgisertib) | MIRM |  | completed, approved | "Atebrioz \| zilurgisertib \| 9/25/2026 \| To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| September 26, 2026 | [ATEBRIOZ® (zilurgisertib) PDUFA date](https://sec-api.dev/pdufa/zilurgisertib) | MIRM |  | completed, approved | "•Presented positive pivotal Phase 2 results from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva (FOP) at ENDO 2026; Prescription Drug User Fee Act (PDUFA) target action date for the zilurgisertib NDA is September 26, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805xexx991.htm)) |
| September 2026 | [Farxiga (dapagliflozin) primary completion](https://sec-api.dev/pdufa/dapagliflozin) | AZN | Chronic Kidney Disease With High Proteinuria | delayed | "NCT06942910 (A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-26 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06942910)) |
| September 27, 2026 | [Relutrigine PDUFA date](https://sec-api.dev/pdufa/relutrigine) | PRAX | SCN2A and SCN8A developmental and epileptic encephalopathies, or DEEs | scheduled | "FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) with a PDUFA target action date of September 27, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/praxisq12026pr.htm)) |
| September 2026 | [Litifilimab primary completion](https://sec-api.dev/pdufa/litifilimab) | BIIB | Lupus Erythematosus, Systemic | delayed | "NCT04961567 (A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-27 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04961567)) |
| September 28, 2026 | [Foralumab trial start](https://sec-api.dev/pdufa/foralumab) | TLSA |  | completed | "Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723069/000121390026103735/ea030682901ex99-1.htm)) |
| September 28, 2026 | [Rinvatercept trial start](https://sec-api.dev/pdufa/rinvatercept) | KROS | Duchenne muscular dystrophy | completed | "On September 28, 2026, Keros Therapeutics, Inc. (the "Company") issued a press release announcing that the first patient was dosed in its Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000056/kros-20260928.htm)) |
| September 28, 2026 | [Prolia® (denosumab) FDA approval](https://sec-api.dev/pdufa/denosumab) | TEVA |  | completed, approved | "On September 28, 2026, we announced that the FDA approved DEGEVMA (denosumab-adet) as a biosimilar to Xgeva® (denosumab)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184326007054/exh_991.htm)) |
| September 28, 2026 | [HUTCHMED (China) Ltd trial start](https://sec-api.dev/companies/hcm/catalysts) | HCM | unresectable, advanced or metastatic solid tumors | completed | "Hong Kong, Shanghai & Florham Park, NJ — Monday, September 28, 2026: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000164825726000061/hcm-ex99d1.htm)) |
| September 28, 2026 | [Expec9v topline data readout](https://sec-api.dev/pdufa/expec9v) | JNJ | Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention | completed | "NCT04899336 (A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-27 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-09-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04899336?tab=results)) |
| September 28, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed | "NCT05007106 (MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-05 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-09-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05007106?tab=results)) |
| September 28, 2026 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | REGN | Paroxysmal Nocturnal Hemoglobinuria | completed | "NCT05133531 (A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05133531)) |
| September 2026 | [Mezigdomide primary completion](https://sec-api.dev/pdufa/mezigdomide) | BMY | Relapsed or Refractory Multiple Myeloma | delayed | "NCT05552976 (A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-28 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05552976)) |
| September 28, 2026 | [INCB099280 primary completion](https://sec-api.dev/pdufa/incb099280) | INCY | Cutaneous Squamous Cell Carcinoma | withdrawn | "NCT05888844 (A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05888844)) |
| September 2026 | [OCU410ST primary completion](https://sec-api.dev/pdufa/ocu410st) | OCGN | Stargardt Disease | delayed | "NCT05956626 (A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-09-28 (ESTIMATED); Lead Sponsor Ocugen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05956626)) |
| September 28, 2026 | [UGN-103 topline data readout](https://sec-api.dev/pdufa/ugn-103) | URGN | Bladder Cancer; Urothelial Carcinoma; Urothelial Carcinoma Bladder | completed | "NCT06331299 (A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-11 (ACTUAL); Lead Sponsor UroGen Pharma Ltd.; Results First Posted 2026-09-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06331299?tab=results)) |
| September 28, 2026 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | Prurigo Nodularis | completed | "NCT06516965 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06516965)) |
| September 28, 2026 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Hidradenitis Suppurativa | completed | "NCT06768671 (An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06768671)) |
| September 29, 2026 | [VYD2311 topline data readout](https://sec-api.dev/pdufa/vyd2311) | IVVD |  | completed, met | "NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, clinically meaningful, and statistically significant topline data from the LIBERTY Phase 3, randomized, double-blind, active controlled study evaluating the safety and tolerability of (1) VYD2311, Invivyd's investigational COVID-directed monoclonal antibody candidate, (2) mRNA-based COVID-19 vaccine COMIRNATY® (mRNA-based COVID-19 vaccine, COVID-19 mRNA vaccine, or COVID vaccine), and (3) VYD2311 co-administered with mRNA-based COVID-19 vaccine." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312526406007/ivvd-ex99_1.htm)) |
| September 29, 2026 | [Reproxalap complete response letter (CRL)](https://sec-api.dev/pdufa/reproxalap) | ALDX | dry eye disease | completed, complete response letter | "Based on the Type D meeting, on September 29, 2026, Aldeyra issued a press release (the Press Release) announcing the intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA's Office of New Drugs (OND), appealing the March 16, 2026 Complete Response Letter that denied approval of a New Drug Application for reproxalap for the treatment of dry eye disease, and the extension of Aldeyra's projected operational cash runway into 2029." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526405954/aldx-20260929.htm)) |
| September 29, 2026 | [ORPATHYS® (savolitinib) NDA/BLA submission](https://sec-api.dev/pdufa/savolitinib) | HCM | with locally advanced or metastatic non-small cell lung cancer | completed | "Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 29, 2026: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that AstraZeneca has submitted a New Drug Application ("NDA") to the US Food and Drug Administration ("FDA") for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") whose tumors have MET overexpression or amplification, and who had disease progression on or after an epidermal growth factor receptor ("EGFR") tyrosine kinase inhibitor ("TKI") therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000164825726000064/hcm-ex99d1.htm)) |
| September 29, 2026 | [Lanifibranor primary completion](https://sec-api.dev/pdufa/lanifibranor) | IVA | NASH - Nonalcoholic Steatohepatitis | completed | "NCT04849728 (A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-29 (ACTUAL); Lead Sponsor Inventiva Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04849728)) |
| September 29, 2026 | [MRNA-1345 topline data readout](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT05127434 (A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-09-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05127434?tab=results)) |
| September 29, 2026 | [Tukysa (tucatinib) topline data readout](https://sec-api.dev/pdufa/tucatinib) | PFE | HER2 Positive Breast Cancer | completed | "NCT05132582 (A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-09-05 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer; Results First Posted 2026-09-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05132582?tab=results)) |
| September 2026 | [Nucala (mepolizumab) primary completion](https://sec-api.dev/pdufa/mepolizumab) | GSK | Eosinophilic Granulomatosis With Polyangiitis | delayed | "NCT05263934 (Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05263934)) |
| September 29, 2026 | [REGN5381 topline data readout](https://sec-api.dev/pdufa/regn5381) | REGN | Heart Failure | completed | "NCT05353166 (REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-02 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals; Results First Posted 2026-09-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05353166?tab=results)) |
| September 29, 2026 | [Balinatunfib primary completion](https://sec-api.dev/pdufa/balinatunfib) | SNY | Colitis Ulcerative; Crohn's Disease | withdrawn | "NCT07222189 (A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-29 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222189)) |
| September 30, 2026 | [RASONQUE (daraxonrasib) FDA approval](https://sec-api.dev/pdufa/daraxonrasib) | RVMD |  | completed, approved | "In the three months ended September 30, 2026, following FDA approval of RASONQUE, the Company determined that the acquired RAS programs IPR&D was complete and no longer indefinite-lived." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1628171/000119312526447253/rvmd-20260930.htm)) |
| September 30, 2026 | [Sonelokimab NDA/BLA submission](https://sec-api.dev/pdufa/sonelokimab) | MLTX | moderate-to-severe hidradenitis suppurativa | completed | "On September 30, 2026, the Company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), seeking approval of sonelokimab (SLK) for the treatment of moderate-to-severe hidradenitis suppurativa (HS) in adults and pediatric patients 12 years of age and older." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000013/moonlake-pressreleasexq320.htm)) |
| September 30, 2026 | [YUVIWEL® (navepegritide) FDA approval](https://sec-api.dev/pdufa/navepegritide) | ASND |  | completed, approved | "Further, the nine months ended September 30, 2026 included the reversal (income) of prior-period write-downs of €10.9 million related to pre-launch inventories for Growth Disorders due to the U.S. FDA approval of YUVIWEL." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000161204226000024/asnd-20260930.htm)) |
| September 30, 2026 | [BRISTOL MYERS SQUIBB CO PDUFA date](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | scheduled | "The FDA has granted the application Priority Review and assigned a PDUFA date of September 30, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/bmy-20260630.htm)) |
| September 30, 2026 | [Pharvaris N.V. topline data readout](https://sec-api.dev/companies/phvs/catalysts) | PHVS |  | scheduled | "We expect to report topline data from this study by September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526345702/phvs-ex99_2.htm)) |
| September 30, 2026 | [MoonLake Immunotherapeutics NDA/BLA acceptance](https://sec-api.dev/companies/mltx/catalysts) | MLTX |  | completed | "As of September 30, 2026, the Company made a total of €7.5 million ($8.1 million using the then applicable exchange rate) in additional milestone payments and accrued €15.0 million ($17.0 million using the period end exchange rate) for a regulatory milestone associated with FDA acceptance of the Company's BLA submission for SLK." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000015/mnlk-20260930.htm)) |
| September 30, 2026 | [Tecentriq® (atezolizumab) FDA approval](https://sec-api.dev/pdufa/atezolizumab) | JAZZ |  | completed, approved | "•On September 30, 2026, the FDA approved the label supplement removing the second-line indication." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000056/a3q26earningsrelease.htm)) |
| September 30, 2026 | [TransportNPC (transportnpc) topline data readout](https://sec-api.dev/pdufa/transportnpc) | RFL |  | completed, missed | "On September 30, 2026, the Company announced topline results from its Phase 3 TransportNPC™ study of Trappsol® Cyclo™, which did not meet its primary endpoint in the overall study population." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113659/ea0309115-10k_rafael.htm)) |
| September 30, 2026 | [LENZ Therapeutics, Inc. FDA approval](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed, approved | "Through September 30, 2026, the Company has devoted substantially all of its efforts to product development, pre-commercial and commercial activities following the FDA approval of VIZZ in July 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000059/lenz-20260930.htm)) |
| September 30, 2026 | [Anaphylm™ (dibutepinephrine) FDA approval](https://sec-api.dev/pdufa/dibutepinephrine) | AQST |  | completed, approved | "Cash Position Supports Anaphylm Review and Launch Preparation 9 $90.3 million in cash and cash equivalents as of September 30, 2026 Potential access to $75 million under a strategic funding agreement with RTW Investments, subject to applicable conditions including FDA approval of Anaphylm An additional $20 million potentially available under the Oaktree Capital Management debt facility, subject to applicable conditions including FDA approval of Anaphylm; no assurance either facility will become available" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000077/corporatepowerpointprese.htm)) |
| September 30, 2026 | [ISEMBYLD (apitegromab) PDUFA date](https://sec-api.dev/pdufa/apitegromab) | SRRK |  | completed, approved | "Apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) review by FDA continues to advance with two fill-finish facilities, representing two independent paths to an FDA approval decision by September 30, 2026 Prescription Drug User Fee Act (PDUFA) date" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000119312526336715/srrk-ex99_1.htm)) |
| September 30, 2026 | [SIL204 trial start](https://sec-api.dev/pdufa/sil204) | SLXN |  | completed | "The increase resulted mainly from an increase in subcontractors and consultants expenses in an aggregate amount of $1.0 million, reflecting our operational ramp-up and preparations required to support our Phase 2/3 clinical trial for SIL204, in which the first patient was dosed on September 30, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/2022416/000117891326005201/zk2636352.htm)) |
| September 30, 2026 | [Camzyos® (mavacamten) label expansion decision](https://sec-api.dev/pdufa/mavacamten) | BMY |  | completed, approved | "NDA214998 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20260930, review_priority PRIORITY; sponsor_name BRISTOL; product CAMZYOS (MAVACAMTEN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214998%22)) |
| September 2026 | [Linerixibat primary completion](https://sec-api.dev/pdufa/linerixibat) | GSK | Cholestasis | delayed | "NCT04167358 (Linerixibat Long-term Safety, and Tolerability Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04167358)) |
| September 2026 | [Litifilimab primary completion](https://sec-api.dev/pdufa/litifilimab) | BIIB | Lupus Erythematosus, Systemic | delayed | "NCT04895241 (A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04895241)) |
| September 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma | delayed | "NCT05557838 (Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05557838)) |
| September 2026 | [Adagrasib oral dose of 400 mg twice daily tablets primary completion](https://sec-api.dev/pdufa/adagrasib-oral-dose-of) | BMY | Advanced NSCLC; Metastatic Lung Cancer | delayed | "NCT05609578 (Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05609578)) |
| September 30, 2026 | [TAK-881 topline data readout](https://sec-api.dev/pdufa/tak-881) | TAK | Primary Immunodeficiency Diseases (PID) | completed | "NCT05755035 (A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-01-20 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-09-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05755035?tab=results)) |
| September 30, 2026 | [INCB099280 primary completion](https://sec-api.dev/pdufa/incb099280) | INCY | Advanced Solid Tumor | withdrawn | "NCT05879822 (A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-30 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05879822)) |
| September 2026 | [Rsvpref3 oa vaccine primary completion](https://sec-api.dev/pdufa/rsvpref3-oa-vaccine) | GSK | Respiratory Syncytial Virus Infections | delayed | "NCT06534892 (An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06534892)) |
| September 30, 2026 | [Tobevibart primary completion](https://sec-api.dev/pdufa/tobevibart) | VIR | Viral Hepatitis | completed | "NCT06903338 (A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ACTUAL); Lead Sponsor Vir Biotechnology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06903338)) |

Other months: https://sec-api.dev/fda-calendar/2026-08 , https://sec-api.dev/fda-calendar/2026-10. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates September 2026: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2026-09

```bibtex
@misc{secapidev_fda_calendar_2026_09_20261116,
  title        = {PDUFA dates September 2026: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2026-09}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2026_09_20261116","title":"PDUFA dates September 2026: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2026-09","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
